RAI Plus Immunotherapy for Recurrent/Metastatic Thyroid Cancers

NCT03215095 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

11

Enrollment

OTHER

Sponsor class

Conditions

Thyroid Cancer

Interventions

DRUG: Durvalumab (Medi4736)
RADIATION: Radioiodine (RAI)

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]
[object Object]